Journal article
Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
Abstract
BACKGROUND: Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016.
OBJECTIVE: Our objective was to assess the safety of idarucizumab among patients who received the drug within the first 3 years of its use in Canada.
Authors
Abdulrehman J; Zarabi S; Elbaz C; de Wit K; Lin Y; Sholzberg M; Selby R
Journal
Research and Practice in Thrombosis and Haemostasis, Vol. 5, No. 5,
Publisher
Elsevier
Publication Date
July 2021
DOI
10.1002/rth2.12535
ISSN
2475-0379